INNOVATION, CUSTOMER FOCUS & OPERATIONAL EXCELLENCE
Delivering Novel Cancer Diagnostic Solutions

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory solutions. Predictive is at the forefront of innovation in improving how cancer is diagnosed and monitored, effectively utilizing a patient’s biomarker information to determine disease status.

INNOVATION

As a leading innovator of proprietary molecular diagnostics, Predictive Biosciences has pioneered the Clinical Intervention Determining Diagnostic (CIDD™) and Multi-Analyte Diagnostic Readout (MADR™) approaches to cancer management, combining the company’s novel clinical approaches and unique biomarkers. These technologies are at the core of Predictive’s CertNDx™ tests, a line of cancer assays enabling physicians to non-invasively determine the absence of cancer in patients with high negative predictive value.

Predictive continues to build an aggressive pipeline of CertNDx tests that can be applied across different cancers. The CertNDx product line will continually evolve as performance is optimized and new biomarkers are added to the portfolio. Incorporated into current standard clinical practice, the CertNDx tests can lead to more effective utilization of existing diagnostic tools, a decrease in unnecessary invasive procedures and ultimately better patient outcomes.

CUSTOMER FOCUS

The company is focused on understanding the needs of physicians and providing valuable diagnostic services and laboratory solutions. The CertNDx tests were developed to deliver clinically relevant information enabling physicians to improve patient management. The first tests are targeted toward the bladder and prostate cancer populations and the large number of individuals undergoing clinical workups for these malignancies.

Molecular diagnostics is the most rapidly growing segment of the U.S. laboratory services market, with bladder cancer and prostate cancer needs alone representing multi-billion dollar opportunities.

OPERATIONAL EXCELLENCE

With quality and customer satisfaction as our key focus, our business philosophy is driven by the continuous evaluation of our customers’ needs and integrating these needs into our business processes. Our laboratories and team of pathologists are committed to providing clinically valuable information in a timely, efficient manner enabling physicians to more effectively manage their patients.

A Brief History

Predictive Biosciences was established in 2006 on the premise that urinary Matrix Metalloproteinase (MMP) biomarkers, discovered at Children’s Hospital Boston, could be utilized to develop new, highly reliable and non-invasive diagnostic tests to more effectively detect and manage the progression of cancer. Today, Predictive’s exclusive portfolio includes both protein biomarkers such as MMP’s and A Disintegrin And Metalloproteinases (ADAM’s), as well as DNA biomarkers such as Fibroblast Growth Factor Receptor 3 (FGFR-3). Detected in urine samples, these biomarkers are also highly correlated with the presence and/or progression of certain cancers. Predictive is advancing the utility of these biomarkers as clinical tests to monitor for disease recurrence and disease-free status, initially in urological cancers.

In January 2010, Predictive Biosciences acquired OncoDiagnostics Laboratory (ODL), a leading Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab based in Cleveland, Ohio. ODL serves a large base of urologists and other subspecialty physicians nationwide and has consistently received top service and satisfaction ratings. As the commercial division of Predictive, ODL will facilitate the market launch of the CertNDx portfolio of novel molecular cancer assays. See www.oncodiagnostic.com to for more information.

Based in Lexington, MA, Predictive is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures, New Enterprise Associates and ProQuest Investments.